Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123951 | 0.87 | TSHR (0.52) | MAPTSMN1; SMN2TSHRLMNAKMT2A | |
| SCHEMBL1123874 | 0.84 | MAPT (0.54) | MAPTL3MBTL1AKR1C3SMN1; SMN2ADK | |
| SCHEMBL1123922 | 0.82 | AKR1C3 (0.46) | MAPTAKR1C3TSHRLMNAABL1 | |
| SCHEMBL27804983 | 0.79 | MAPT (0.46) | MAPTL3MBTL1TSHRLMNAMEN1 | |
| SCHEMBL1123782 | 0.79 | LMNA (0.47) | MAPTSMN1; SMN2TSHRLMNAABL1 | |
| SCHEMBL1123801 | 0.77 | ALDH1A1 (0.49) | MAPTTSHRLMNAMEN1KMT2A | |
| SCHEMBL1123984 | 0.75 | AKR1C3 (0.51) | AKR1C3SMN1; SMN2TSHRLMNAMEN1 | |
| SCHEMBL21690 | 0.73 | MAPT (0.66) | MAPTAKR1C3SMN1; SMN2TSHRLMNA | |
| SCHEMBL1123934 | 0.73 | LMNA (0.51) | MAPTL3MBTL1AKR1C3SMN1; SMN2LMNA | |
| SCHEMBL1123709 | 0.73 | LMNA (0.51) | MAPTL3MBTL1AKR1C3SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| CN-102046609-A | pyrimidine derivative having cell-protective effect and use thereof | ZENYAKU KOGYO KK | 2011-05-04 | — | — | CN | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009123221-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | 全薬工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | CASP3, DPYD, CASP1 | MAPT 350/4885L3MBTL1 701/4885AKR1C3 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.